Allist Pharmaceuticals Co., Ltd. (SHA: 688578) announced that China’s regulatory authorities have granted Breakthrough Therapy Designation (BTD) for its investigational combination of glecirasib and AST24082 as first-line treatment for patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) harboring KRAS G12C mutations and PD-L1 expression < 50%.
Contents
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | China National Medical Products Administration (NMPA) |
| Designation | Breakthrough Therapy Designation (BTD) |
| Product Combination | Glecirasib + AST24082 (oral capsules) |
| Indication | First-line treatment of KRAS G12C-mutant NSCLC with PD-L1 < 50% |
| Patient Population | Locally advanced or metastatic non-squamous NSCLC |
| Development Stage | Early clinical exploratory studies completed; pivotal trials expected to follow |
Drug Profile & Mechanism of Action
- Glecirasib: KRAS G12C inhibitor targeting the specific oncogenic mutation driving tumor growth
- AST24082: Novel, highly selective SHP2 inhibitor in oral capsule form that enhances KRAS pathway inhibition
- Combination Rationale: Dual blockade of KRAS G12C and SHP2 produces synergistic anti-tumor effects by comprehensively inhibiting the MAPK signaling pathway
- Administration: Oral regimen offering potential convenience advantages over intravenous standard-of-care therapies
Clinical Data – Early Exploratory Studies
| Endpoint | Result |
|---|---|
| Patient Population | First-line advanced KRAS G12C-mutant NSCLC |
| Median Follow-up | 14.4 months |
| Confirmed Objective Response Rate (ORR) | 71% |
| Median Progression-Free Survival (PFS) | 12.2 months |
| Safety Profile | Manageable with no unexpected toxicities |
| Comparative Benchmark | Superior efficacy vs. current first-line standard (immunotherapy + chemotherapy) |
Market Context & Competitive Landscape
| Aspect | Analysis |
|---|---|
| Target Population Size | KRAS G12C mutations occur in ~13% of NSCLC cases in China, representing ~80,000 annual incident cases |
| Current Standard of Care | PD-1/PD-L1 immunotherapy combined with platinum-based chemotherapy for PD-L1 < 50% patients |
| Unmet Need | Limited targeted therapy options for KRAS G12C-mutant NSCLC in first-line setting |
| Competitive Differentiation | First oral combination specifically targeting KRAS G12C + SHP2 pathway in Chinese development |
| Global Context | Builds on emerging global interest in KRAS G12C inhibitors (e.g., sotorasib, adagrasib) with novel combination approach |
Strategic Implications & Commercial Outlook
- First-Mover Advantage: Potential to become first approved targeted therapy for KRAS G12C-mutant NSCLC in China’s first-line setting
- Market Premium: Targeted therapies typically command significant pricing premiums over chemotherapy-based regimens
- Development Acceleration: BTD status enables expedited regulatory review and potential priority approval pathways
- Global Expansion Potential: Strong clinical data could support international partnerships or regulatory filings in other markets
- Pipeline Validation: Success validates Allist’s precision oncology strategy and SHP2 inhibitor platform technology
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical development timelines, regulatory outcomes, and commercial potential. Actual results may differ due to risks including pivotal trial outcomes, regulatory decisions, and competitive developments in the KRAS-targeted therapy space.-Fineline Info & Tech
